Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) is a treatable leukemia managed with BCR-ABL1 kinase inhibitors.
• Despite available therapies, a significant patient subset experiences resistance or intolerance to tyrosine kinase inhibitors (TKIs).
• Unmet needs include managing highly selective resistant disease, multi-TKI resistant CML, and advanced phase leukemia.

Purpose of the Study:

• To review treatment expectations and response milestones in CML therapy.
• To define inadequate response to therapy and critically evaluate current strategies.
• To highlight novel agents in development for CML addressing unmet needs.

Main Methods:

• Review of current literature on CML treatment strategies and novel therapeutic agents.
• Analysis of treatment response, resistance mechanisms, and adverse event profiles.
• Evaluation of emerging therapies targeting ABL1 kinase, including those addressing specific mutations like T315I.

Main Results:

• New potent ABL1 inhibitors are emerging with enhanced selectivity and improved adverse event profiles.
• Novel approaches targeting the myristoyl pocket of ABL1 show promising early clinical results.
• These advancements aim to address resistance, including the T315I mutation, and intolerance issues.

Conclusions:

• Despite progress, challenges in CML treatment persist, necessitating novel therapeutic strategies.
• Emerging agents and alternative inhibition approaches hold promise for overcoming TKI resistance and intolerance.
• Continued research is crucial to address unmet needs in advanced and resistant CML cases.